St. Jude Medical

Latest Headlines

Latest Headlines

St. Jude flexible cardiac catheter approved in EU, aims for FDA

St. Jude Medical is hoping to strengthen its franchise in ablation catheters--thin, flexible wires inserted non-surgically into the heart to treat cardiac arrhythmia. Its FlexAbility irrigated ablation catheter has garnered a CE Mark in Europe, where it has marketed the TactiCath contact-force sensing irrigated ablation catheter since 2012. The company hopes to get FDA approval by year end for both FlexAbility and TactiCath.

Amid positive Q2 sales, St. Jude looks to renal denervation as untapped niche

St. Jude Medical is celebrating positive second-quarter sales fueled by tried-and-true products, but the devicemaker wants to capitalize on an untapped niche in the coming year by focusing on renal denervation.

St. Jude Medical charts positive Q2 numbers, thanks in part to recent M&A

St. Jude Medical posted slight increases in second quarter sales, riding the tailwinds of recent M&A deals and the continued success of its cardiac rhythm management unit.

St. Jude shells out $200M for chronic pain therapy manufacturer NeuroTherm

St. Jude Medical signed on the dotted line to acquire interventional pain management therapy manufacturer NeuroTherm for approximately $200 million in cash, strengthening its foothold in the chronic pain market.

St. Jude to take over CardioMEMS following FDA approval

St. Jude Medical will exercise its exclusive option to purchase CardioMEMS, maker of the now FDA approved HF System for monitoring heart failure.

St. Jude touts renal denervation data, but U.S. approval still a long way off

St. Jude Medical bucked the trend of bad renal denervation news, touting the newly released data from its studies of the CE-marked EnligHTN renal denervation system at the EuroPCR cardiovascular interventions conference in Paris.

St. Jude Medical achieves first U.S. implants of its TAVR system

St. Jude Medical completed the first U.S. implants of its transcatheter aortic valve system, moving the company one step closer to winning coveted stateside approval for its device.

St. Jude's a-fib tech aces trial as FDA awaits

St. Jude Medical's much-vaunted TactiCath device came through in a sizable U.S. trial, the company said, setting the stage for a final FDA decision and a chance at a bigger share of the electrophysiology market.

St. Jude rides strong ICD sales to a first-quarter bump

Despite long-running headwinds, St. Jude Medical pulled off an increase in implanted defibrillator revenue in the first quarter, helping the company swing to a small rise in sales.

St. Jude aims to jump-start the cardiac device space with new pacers and defibrillator leads

St. Jude Medical is confronting a flat pacemaker market and continued fallout from faulty defibrillator leads with a rollout of new products in both spaces. The hope: Next-generation improvements will spur new market interest and greater revenue.